LRRK2 kinase inhibitors or LRRK2 knockdown approaches may hold promise as potential therapeutic strategies for PD as they can prevent over-phosphorylation of LRRK2 substrates, eventually aiding in restoration of the E-L system to enhance clearance of α-synuclein aggregates. The gene discussed is LRRK2; the disease is Parkinson disease.